Highlights Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Real-time Estimate Cboe BZX Other stock markets 03:07:03 2024-06-10 pm EDT			5-day change	1st Jan Change
32.08 ^USD	-12.30%		-11.11%	+54.72%

Jun. 04	Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target	MT
May. 24	Mizuho Securities Starts Cartesian Therapeutics With Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cartesian Gets Regenerative Medicine Advanced Therapy Label for Myasthenia Gravis Drug Candidate	May. 22	MT
Cartesian Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for Descartes-08 for the Treatment of Myasthenia Gravis	May. 22	CI
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	Mar. 14	CI
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	Mar. 05	CI
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	Jan. 08	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Cartesian Therapeutics, Inc. acquired Selecta Biosciences, Inc. for approximately $380 million, in a reverse merger transaction.	Nov. 12	CI
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement	23-10-31	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Selecta Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Top Premarket Gainers	23-03-21	MT
Selecta Biosciences, Inc Announces Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint	23-03-21	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-02	CI
Selecta Biosciences Signs Licensing Deal With Astellas for IgG Protease Candidate Xork; Shares Rise	23-01-09	MT
Selecta Biosciences, Inc. and Astellas Pharma Inc. Announce Exclusive Licensing and Development Agreement for Xork IgG Protease	23-01-09	CI
Selecta Biosciences Picks New Candidate for Kidney Disease Program	22-12-14	MT
Selecta Biosciences Announces Next Generation Iga Protease Clinical Candidate Selection for Iga Nephropathy Program	22-12-14	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Highlights

Filters